Related Experiment Video

Updated: Oct 1, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Targeting TNFR2 in Cancer: All Roads Lead to Rome

Jingchao Bai1,2,3, Bowen Ding2,3,4, Hui Li1,2,3

  • 1Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Frontiers in Immunology
|March 7, 2022
PubMed

Insights

Tumor necrosis factor receptor 2 (TNFR2) is a key target in cancer. Blocking or activating TNFR2 shows promise for cancer treatment by modulating the tumor microenvironment (TME) and immune responses.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumor necrosis factor receptor 2 (TNFR2) plays a critical role in the tumor microenvironment (TME).
  • TNFR2 is overexpressed in tumor cells and crucial for immunosuppressive cells like regulatory T cells (Tregs).
  • Both blocking and activating TNFR2 present potential therapeutic strategies in cancer treatment.

Purpose of the Study:

  • To review current drugs targeting TNFR2 in clinical trials or preclinical development.
  • To explore the mechanisms of action for both TNFR2-blocking and TNFR2-activating agents.
  • To summarize the therapeutic potential of TNFR2 modulation in cancer.

Main Methods:

  • Literature review of clinical trials and preclinical studies on TNFR2-targeting drugs.
  • Analysis of the role of TNFR2 in tumor immunology and cancer progression.
  • Exploration of the molecular mechanisms underlying TNFR2 blockade and activation.

Main Results:

  • Several drugs targeting TNFR2 are in various stages of development.
  • Both inhibition and activation of TNFR2 have demonstrated anti-tumor effects in preclinical models.
  • The specific effects of TNFR2 modulation depend on the context of the tumor and immune cells involved.

Conclusions:

  • TNFR2 is a promising immune checkpoint target for cancer therapy.
  • Targeting TNFR2, through blockade or activation, offers diverse strategies for cancer treatment.
  • Further research is needed to elucidate the complex mechanisms and optimize therapeutic applications of TNFR2-targeting drugs.
Keywords:
TNFR2Tregagonistantagonisttumor microenvironment

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

842
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
708
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K